Effects of Dapagliflozin on Body Weight in Patients with Type 2 Diabetes Mellitus: Evidence‑based Practice

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2024 Mar 13

PMID 38476895

Authors

Yan Han

Ya-Feng Li

Chao-Wei Ye

Yao-Yang Gu

Xiao Chen

Qian Gu

Qiang-Qiang Xu

Xian-Ming Wang

Su-Mei He

Dong-Dong Wang

Affiliations

Soon will be listed here.

Abstract

The dose-dependent pharmacological response to dapagliflozin in patients with type 2 diabetes mellitus (T2DM) with regard to weight loss remain unknown. The aim of the present study was to investigate the effects of dapagliflozin on weight loss in patients with T2DM. A total of 8,545 patients with T2DM from 24 randomized controlled trials reported in the literature were selected for inclusion in the study. Data from these trials were analyzed using maximal effect (E) models with nonlinear mixed effects modeling; the evaluation index was the body weight change rate from baseline values. Patients treated with 2.5 mg/day dapagliflozin exhibited an E of -3.04%, and the time taken for therapy to reach half of the E (ET) was estimated to be 30.8 weeks for patients treated with this dose. Patients treated with 5, 10 and 20 mg/day dapagliflozin exhibited E values of -6.57, -4.12 and -3.23%, respectively, and their ET values were estimated to be 27.3, 20.4 and 4.23 weeks, respectively. The data indicated ideal linear relationships between individual predictions and observations, suggesting the optimal fitting of the final models. The present study is the first systematic analysis of the effect of dapagliflozin on weight loss in patients with T2DM. The application of dapagliflozin at 5 mg/day exhibited a greater weight loss effect compared with the other doses used, and the weight loss onset time shortened as the dose of dapagliflozin increased.

Citing Articles

The effects of Dapagliflozin in a real-world population of HFrEF patients with different hemodynamic profiles: worse is better.

Loria F, Mone P, Rispoli A, Di Fonzo R, Masarone D, Mancusi C Cardiovasc Diabetol. 2024; 23(1):423.

PMID: 39578847 PMC: 11583416. DOI: 10.1186/s12933-024-02515-5.

References

Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T . Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019; 73(5):e13335. DOI: 10.1111/ijcp.13335. View

Yamakage H, Tanaka M, Inoue T, Odori S, Kusakabe T, Satoh-Asahara N . Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial. J Diabetes Investig. 2019; 11(3):653-661. PMC: 7232283. DOI: 10.1111/jdi.13179. View

Grandy S, Hashemi M, Langkilde A, Parikh S, Sjostrom C . Changes in weight loss-related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin. Diabetes Obes Metab. 2014; 16(7):645-50. DOI: 10.1111/dom.12263. View

Gonzalez-Muniesa P, Martinez-Gonzalez M, Hu F, Despres J, Matsuzawa Y, Loos R . Obesity. Nat Rev Dis Primers. 2017; 3:17034. DOI: 10.1038/nrdp.2017.34. View

Mathieu C, Ranetti A, Li D, Ekholm E, Cook W, Hirshberg B . Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes. Diabetes Care. 2015; 38(11):2009-17. DOI: 10.2337/dc15-0779. View

Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel S . Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32(7):1243-52. DOI: 10.1185/03007995.2016.1168291. View

List J, Woo V, Morales E, Tang W, Fiedorek F . Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2008; 32(4):650-7. PMC: 2660449. DOI: 10.2337/dc08-1863. View

Einarson T, Acs A, Ludwig C, Panton U . Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018; 17(1):83. PMC: 5994068. DOI: 10.1186/s12933-018-0728-6. View

Bailey C, Gross J, Hennicken D, Iqbal N, Mansfield T, List J . Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013; 11:43. PMC: 3606470. DOI: 10.1186/1741-7015-11-43. View

10.

Iacobellis G, Gra-Menendez S . Effects of Dapagliflozin on Epicardial Fat Thickness in Patients with Type 2 Diabetes and Obesity. Obesity (Silver Spring). 2020; 28(6):1068-1074. DOI: 10.1002/oby.22798. View

11.

Fioretto P, Mansfield T, Ptaszynska A, Yavin Y, Johnsson E, Parikh S . Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs Aging. 2016; 33(7):511-22. PMC: 4937081. DOI: 10.1007/s40266-016-0382-1. View

12.

Feng M, Lv H, Xu X, Wang J, Lyu W, Fu S . Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials. Medicine (Baltimore). 2019; 98(30):e16575. PMC: 6709066. DOI: 10.1097/MD.0000000000016575. View

13.

Gilor C, Niessen S, Furrow E, DiBartola S . What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters. J Vet Intern Med. 2016; 30(4):927-40. PMC: 5108445. DOI: 10.1111/jvim.14357. View

14.

Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J . Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014; 16(11):1102-10. DOI: 10.1111/dom.12325. View

15.

Cefalu W, Leiter L, de Bruin T, Gause-Nilsson I, Sugg J, Parikh S . Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care. 2015; 38(7):1218-27. PMC: 4831907. DOI: 10.2337/dc14-0315. View

16.

Ji L, Ma J, Li H, Mansfield T, Tjoen C, Iqbal N . Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study. Clin Ther. 2014; 36(1):84-100.e9. DOI: 10.1016/j.clinthera.2013.11.002. View

17.

Kaku K, Maegawa H, Tanizawa Y, Kiyosue A, Ide Y, Tokudome T . Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014; 5(2):415-33. PMC: 4269643. DOI: 10.1007/s13300-014-0086-7. View

18.

Strojek K, Yoon K, Hruba V, Elze M, Langkilde A, Parikh S . Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011; 13(10):928-38. DOI: 10.1111/j.1463-1326.2011.01434.x. View

19.

Gerich J . Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010; 27(2):136-42. PMC: 4232006. DOI: 10.1111/j.1464-5491.2009.02894.x. View

20.

Zhang M, Zhang L, Wu B, Song H, An Z, Li S . Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2013; 30(3):204-21. DOI: 10.1002/dmrr.2479. View